指南与共识心脑血管急症重症综合管理与镇静镇痛

德国共识:定义难治性全身型肌重症肌无力的总分评分

A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus.
指南 / 共识 · J Cent Nerv Syst Dis · 2021-02-01
一句话结论德国肌无力基金会德尔菲共识提出总分评分(≥20 分提示难治性全身型肌重症肌无力),用于临床决策与依库珠单抗适应证判定。

该共识由德国肌无力基金会医学顾问委员会 12 名成员按德尔菲共识方法学完成 4 轮共识,并结合 2004–2020 年文献调查,预先设定共识标准。评分涵盖疾病严重度、既往治疗无效、因副作用停药和长期入住重症监护室 4 个类别,共 13 个评分条目,总分≥20 分提示难治性全身型肌重症肌无力状态。最终德尔菲过程达成一致评分共识。作者建议该总分评分用于定义全身型肌重症肌肌无力治疗难治状态,除明确依库珠单抗指征外,便于临床决策并为探索新疗法的临床研究提供纳入标准。

要点

  • 德尔菲共识提出总分评分,总分≥20 分提示难治性全身型肌重症肌肌无力(TRgMG)状态。
  • 评分含 4 个类别共 13 个条目:疾病严重度、既往治疗无效、因副作用停药、长期入住重症监护室。
  • 共识由德国肌无力基金会医学顾问委员会 12 名成员经 4 轮德尔菲共识达成一致。
  • 作者建议该评分用于明确依库珠单抗适应证并作为临床研究纳入标准。
  • 作者认为该评分易于操作,可辅助临床决策。

适用人群与场景

  • 全身型肌重症肌无力(generalised myasthenia gravis)患者,用于判定治疗难治状态。

诊断标准与关键阈值

  • 总分评分≥20 分提示难治性全身型肌重症肌肌无力(TRgMG)状态。
  • 评分涵盖疾病严重度、既往治疗无效、因副作用停药、长期入住重症监护室 4 个类别,共 13 个评分条目。

研究设计与关键结果

  • 共识采用德尔菲共识方法学,由德国肌无力基金会医学顾问委员会 12 名成员完成 4 轮共识,并做 2004–2020 年文献调查,预先设定共识标准。
  • 评分含 4 个类别共 13 个评分条目,总分≥20 分提示 TRgMG 状态。
  • 德尔菲过程最终达成一致评分共识。

证据类型、等级与局限

  • 证据类型:德尔菲共识(德国肌无力基金会医学顾问委员会 12 名成员,4 轮共识)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者建议用总分评分(≥20 分)定义全身型肌重症肌肌无力的治疗难治状态,以明确依库珠单抗的适应证。
  • 作者认为该评分易于操作,可辅助临床决策,并为探索肌重症肌肌无力新疗法的临床研究提供纳入标准。

指南或共识出处

  • 德国肌无力基金会共识声明(German Myasthenia Foundation consensus statement)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: In 2017, eculizumab has been approved for treatment-refractory generalised myasthenia gravis (TRgMG). The German Myasthenia Foundation has published a consensus statement on the use of eculizumab, with a recent update. However, a treatment-refractory state is still ill-defined and the term warrants further clarification. We aimed at developing a sum score to operationalise the definition of a TRgMG status, which is easy- to-handle in clinical decision making.

METHODS: We established a structured consensus process according to the Delphi consensus methodology, with 12 members of the medical advisory board of the German Myasthenia Foundation. Accordingly, 4 consensus rounds were accomplished. Additionally, a literature survey covering the years 2004-2020 was done and relevant information offered to the consensus group. Consensus criteria were predefined. In the consensus process the relative importance of scoring items were to be consented, with a sum score of 20 and above indicating a TRgMG status.

RESULTS: The sum score considers the categories disease severity, inefficiency of antecedent therapies, cessation of therapies due to side effects, and long term stay on the intensive care unit. Categories were specified by a total of 13 scoring items. Eventually, the Delphi process developed an unanimous scoring consensus.

CONCLUSION: We suggest a sum score to define treatment refractory state in generalised myasthenia gravis. Beyond clarifying the indication of eculizumab, this easy-to-handle score facilitates clinical decision making and offers new inclusion criteria for clinical studies that explore new therapeutic perspectives in myasthenia gravis treatment.

来源:J Cent Nerv Syst Dis,查看原文。版权归原作者所有。

参考来源

  1. Schroeter M, Berger B, Blaes F, et al. A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus. J Cent Nerv Syst Dis. 2021. PMID: 33597816. doi:10.1177/1179573521989151

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。